Opportunity Information: Apply for CDC RFA OE15 1504
Apply for CDC RFA OE15 1504
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Domestic Laboratory Biosafety for Ebola and other Highly Infectious Diseases" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.322 CSELS Partnership Strengthening Public Health Laboratories.
- This funding opportunity was created on Apr 1, 2015 and posted on Mar 31, 2015.
- Applicants must submit their applications by May 1, 2015 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on 5/1/2015.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,200,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Sole Source to the Association of Public Health Laboratories (APHL)
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Domestic Laboratory Biosafety for Ebola and other Highly Infectious Diseases" is a CDC-funded cooperative agreement designed to strengthen biosafety practices in U.S. public health and clinical laboratories that may handle specimens containing highly infectious pathogens, including Ebola. The core aim is to support the Association of Public Health Laboratories (APHL) in building and delivering a coordinated laboratory safety program that improves preparedness and reduces occupational and public risk when testing or handling specimens associated with high-consequence infectious diseases.
The program is built around several practical support functions for laboratories. First, it emphasizes access to subject matter experts who specialize in clinical and public health laboratory safety for infectious agents, with explicit attention to highly infectious agents like Ebola. This expert access is meant to help laboratories interpret and apply biosafety principles in real-world testing environments, including decisions about specimen handling, workflow design, and safe testing practices. Second, it funds coordination and information-sharing so laboratories can exchange best practices, lessons learned, and effective approaches for safe specimen handling and testing. This reflects an understanding that consistent, widely shared procedures and peer-to-peer learning can improve safety performance across many sites more quickly than isolated efforts.
A third major component is direct assistance for laboratories to assess whether their training, facilities, and equipment are sufficient for safe handling and testing of specimens that could contain highly infectious agents. In practice, this would typically involve structured reviews of biosafety readiness: whether staff have the right competencies, whether the physical lab space and engineering controls are appropriate, and whether necessary safety equipment and supplies are available and correctly used. The fourth component is training focused on laboratory safety risk assessment and risk mitigation. That emphasis signals a shift from simple checklist compliance toward a risk-based approach, where laboratories identify specific hazards associated with procedures and specimens, evaluate exposure pathways, and implement mitigation strategies such as safer work practices, appropriate personal protective equipment, engineering controls, and administrative controls.
From an administrative standpoint, this opportunity was issued by the Centers for Disease Control and Prevention under Funding Opportunity Number CDC RFA OE15-1504. It falls under the discretionary funding category, uses a cooperative agreement mechanism (indicating substantial CDC involvement or collaboration during the project), and is classified within the health funding activity category. The CFDA number listed is 93.322 (CSELS Partnership Strengthening Public Health Laboratories). The estimated total funding amount is $2,200,000, with one expected award, and there is no cost sharing or matching requirement.
Eligibility was limited as a sole source award to APHL, meaning the CDC intended to fund APHL specifically rather than run an open competition among multiple organizations. Key dates show it was posted March 31, 2015, created April 1, 2015, and had submission instructions for electronic applications with deadlines noted as 11:59 p.m. ET (with references to May 1, 2015 and also May 11, 2015 in the announcement text). The opportunity was archived May 31, 2015. For access issues related to the full announcement, the listed contact was Greg Jones at the CDC (GJJ1@cdc.gov), with grants policy support indicated.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled Domestic Laboratory Biosafety for Ebola and other Highly Infectious Diseases.
Which federal agency issued this funding opportunity?
The opportunity was issued by the Centers for Disease Control and Prevention (CDC).
What type of funding mechanism is being used?
This is a cooperative agreement, which generally indicates substantial CDC involvement or collaboration during the project period.
What is the main purpose of the cooperative agreement?
The core purpose is to strengthen biosafety practices in U.S. public health and clinical laboratories that may handle specimens containing highly infectious pathogens, including Ebola. The program is intended to improve preparedness and reduce occupational and public risk when testing or handling specimens associated with high-consequence infectious diseases.
Who is intended to be supported through this award?
The cooperative agreement is designed to support the Association of Public Health Laboratories (APHL) in building and delivering a coordinated laboratory safety program.
What pathogens or hazards are in scope for this program?
The program focuses on specimens that could contain highly infectious pathogens, with explicit attention to Ebola, and more broadly addresses high-consequence infectious diseases.
What are the main program components described in the announcement?
The announcement describes four practical support functions:
- Access to subject matter experts specializing in clinical and public health laboratory safety for infectious agents, including highly infectious agents like Ebola.
- Coordination and information-sharing so laboratories can exchange best practices, lessons learned, and effective approaches for safe specimen handling and testing.
- Direct assistance to laboratories to assess whether training, facilities, and equipment are sufficient for safe handling and testing of potentially highly infectious specimens.
- Training on laboratory safety risk assessment and risk mitigation, emphasizing a risk-based approach to identifying hazards and applying controls.
What does "access to subject matter experts" mean in practical terms?
It refers to providing laboratories access to biosafety specialists who can help interpret and apply biosafety principles in real testing environments. Examples mentioned include guidance related to specimen handling decisions, workflow design, and safe testing practices for highly infectious agents.
What kinds of "coordination and information-sharing" activities are envisioned?
The announcement emphasizes enabling laboratories to share best practices and lessons learned. The intent is to improve safety performance across many sites by promoting consistent, widely shared procedures and peer-to-peer learning.
What does the "direct assistance" component help laboratories evaluate?
Direct assistance is described as helping laboratories assess readiness across three areas:
- Training: whether staff have the right competencies.
- Facilities: whether physical space and engineering controls are appropriate.
- Equipment: whether necessary safety equipment and supplies are available, correctly used, and adequate for safe handling and testing.
What is meant by a risk-based approach to biosafety in this program?
The training focus is described as moving beyond simple checklist compliance toward risk assessment and risk mitigation. This includes identifying hazards tied to specific procedures and specimens, evaluating exposure pathways, and implementing mitigation strategies such as safer work practices, appropriate personal protective equipment (PPE), engineering controls, and administrative controls.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number listed is CDC RFA OE15-1504.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.322, described as CSELS Partnership Strengthening Public Health Laboratories.
What is the estimated total funding amount?
The estimated total funding amount is $2,200,000.
How many awards were expected under this opportunity?
The opportunity indicated one expected award.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was limited as a sole source award to APHL, meaning CDC intended to fund APHL specifically rather than conduct an open competition among multiple applicants.
Does this appear to be an open competitive grant opportunity?
No. Based on the announcement details, this was a sole source opportunity limited to APHL.
When was the opportunity posted and created?
It was posted March 31, 2015, and created April 1, 2015.
What were the application submission method and deadline time?
The announcement referenced electronic applications and noted a deadline time of 11:59 p.m. ET.
What application due date should applicants have followed?
The text referenced deadlines associated with May 1, 2015 and also May 11, 2015. The announcement contains both dates as noted in the provided information.
What is the status of this funding opportunity now?
The opportunity was archived May 31, 2015.
Which funding category and activity area does this opportunity fall under?
It falls under the discretionary funding category and is classified within the health funding activity category.
Who was listed as the contact for access issues related to the full announcement?
The listed contact was Greg Jones at CDC, email: GJJ1@cdc.gov. The announcement also indicated grants policy support.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color at Risk for and Living with HIV Infection
Previous opportunity: Office of Innovation and Improvement Development grants Pre Application CFDA Number 84.411P
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA OE15 1504
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA OE15 1504) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color at Risk for and Living with HIV Infection Apply for CDC RFA PS15 1509 Funding Number: CDC RFA PS15 1509 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,333,333 |
| NIAMS Clinical Trial Planning Cooperative Agreement (U34) Apply for PAR 15 166 Funding Number: PAR 15 166 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Preventive Medicine Residency with Integrative Health Care Training Program Apply for HRSA 15 143 Funding Number: HRSA 15 143 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Department Demonstration Projects to Reduce HIV Infections and Improve Engagement in HIV Medical Care among Men Who Have Sex with Men (MSM) and Transgender Persons Apply for CDC RFA PS15 1506 Funding Number: CDC RFA PS15 1506 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $7,000,000 |
| Training and Technical Assistance for Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color At Risk for and Living with HIV Infection Apply for CDC RFA PS15 1510 Funding Number: CDC RFA PS15 1510 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Request for Information for RFI 674 15 RHAP 001 Apply for RFI 674 15 RHAP 001 Funding Number: RFI 674 15 RHAP 001 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| HIV Vaccine Research and Design (HIVRAD) Program (P01) Apply for PAR 15 164 Funding Number: PAR 15 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Training and Technical Assistance Cooperative Agreements (NCAs) Apply for HRSA 15 140 Funding Number: HRSA 15 140 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 15 165 Funding Number: PAR 15 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Health Action Learning Initiative (THALI) Apply for RFA 386 15 000001 Funding Number: RFA 386 15 000001 Agency: India USAID New Delhi Category: Health Funding Amount: $9,500,000 |
| NIBIB Research Education Programs for Residents and Clinical Fellows (R25) Apply for PAR 15 167 Funding Number: PAR 15 167 Agency: National Institutes of Health Category: Health Funding Amount: $70,000 |
| PPHF 2015 Cooperative Agreements for State Sponsored Youth Suicide Prevention and Early Intervention (PPHF 2015) Apply for SM 15 004 Funding Number: SM 15 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $736,000 |
| Alzheimers Drug Development Program (U01) Apply for PAR 15 174 Funding Number: PAR 15 174 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| PPHF 2015 Empowering Older Adults and Adults with Disabilities through Chronic Disease Self Management Education Programs Financed Solely by 2015 Prevention and Public Health Funds (PPHF 2015) Apply for HHS 2015 ACL AOA CS 0094 Funding Number: HHS 2015 ACL AOA CS 0094 Agency: Administration for Community Living Category: Health Funding Amount: $900,000 |
| Epicenters for the Prevention of Healthcare Associated Infections (HAI) Cycle II Apply for RFA CK 15 004 Funding Number: RFA CK 15 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,200,000 |
| Native Hawaiian Health Care Improvement Act Apply for HRSA 15 017 Funding Number: HRSA 15 017 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01) Apply for PAR 15 172 Funding Number: PAR 15 172 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Oral Immune System Plasticity in Chronic HIV Infection Under Treatment and Oral Co Infections (R01) Apply for RFA DE 16 002 Funding Number: RFA DE 16 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pre Application for Collaborative Innovation Award, CTSA Program (X02) Apply for PAR 15 173 Funding Number: PAR 15 173 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Methods Development in Natural Products Chemistry (R41/R42) Apply for RFA AT 16 004 Funding Number: RFA AT 16 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA OE15 1504", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.